Victory Capital Management Inc. Increases Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Victory Capital Management Inc. raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 76.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,057 shares of the company’s stock after buying an additional 3,488 shares during the quarter. Victory Capital Management Inc.’s holdings in TransMedics Group were worth $502,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Quarry LP boosted its position in shares of TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the last quarter. National Bank of Canada FI boosted its position in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares during the last quarter. Hager Investment Management Services LLC bought a new position in shares of TransMedics Group during the 4th quarter valued at approximately $33,000. Sachetta LLC bought a new position in shares of TransMedics Group during the 4th quarter valued at approximately $40,000. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $149,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on TMDX shares. Piper Sandler lowered their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Robert W. Baird lowered their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Stock Up 0.3 %

NASDAQ:TMDX opened at $69.05 on Friday. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a market cap of $2.32 billion, a price-to-earnings ratio of 73.46 and a beta of 2.12. The stock has a fifty day simple moving average of $68.12 and a 200-day simple moving average of $91.06. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.